Suggested remit: To appraise the clinical and cost effectiveness of avapritinib within its marketing authorisation for treating moderate to severe indolent systemic mastocytosis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6578
Provisional Schedule
- Committee meeting: 1:
- 06 May 2026
- Expected publication:
- 03 September 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
Stakeholders
- Companies sponsors
- Blueprint Medicines (avapritinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- UK Mastocytosis support group
- Professional groups
- Association of Cancer Physicians
- British Association of Dermatologists
- British Society for Immunology
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 October 2025 | To appraise the clinical and cost effectiveness of Avapritinib within its marketing authorisation for treating systemic mastocytosis ID6578 |
| 23 September 2025 | Invitation to participate |
| 31 July 2025 - 29 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 31 July 2025 | In progress. Scoping commenced. |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual